<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">28632</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Spontaneous clearance of the human papilloma virus as a result of suppressive therapy with acyclic nucleosides of a recurrent herpes-viral infection</article-title><trans-title-group xml:lang="ru"><trans-title>Спонтанный клиренс вируса папилломы человека в результате супрессивной терапии ациклическими нуклеозидами рецидивирующей герпес-вирусной инфекции, локализованной в области гениталий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tapilskaya</surname><given-names>N I</given-names></name><name xml:lang="ru"><surname>Тапильская</surname><given-names>Н И</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. акушерства и гинекологии (с курсом гинекологии детского и подросткового возраста), проф. каф. онкологии, детской онкологии и лучевой терапии ФГБОУ ВО СПбГПМУ</p></bio><email>tapnatalia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorobtsova</surname><given-names>I N</given-names></name><name xml:lang="ru"><surname>Воробцова</surname><given-names>И Н</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. акушерства и гинекологии (с курсом гинекологии детского и подросткового возраста) ФГБОУ ВО СПбГПМУ</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Glushakov</surname><given-names>R I</given-names></name><name xml:lang="ru"><surname>Глушаков</surname><given-names>Р И</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, и. о. зав. отд-нием вспомогательных репродуктивных технологий клиники акушерства и гинекологии ФГБВОУ ВО «ВМА им. С.М.Кирова»</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saint Petersburg Pediatric University of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБВОУ ВО «Военно-медицинская академия им. С.М.Кирова» Минобороны России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2017</year></pub-date><volume>19</volume><issue>3</issue><issue-title xml:lang="en">VOL 19, NO3 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 19, №3 (2017)</issue-title><fpage>55</fpage><lpage>61</lpage><history><date date-type="received" iso-8601-date="2020-04-09"><day>09</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/28632">https://gynecology.orscience.ru/2079-5831/article/view/28632</self-uri><abstract xml:lang="en"><p>Background. Genital human papillomavirus (HPV) infection is not effectively controlled and treated. Current dates suggest that 80% cases of HPV infections are transient and clear spontaneously, it is connected with the deterministic immune response. Results of several independent studies suggest that HSV-2 infections correlate with a higher than normal incidence of cervical cancer. Objectives. This study demonstrated a spontaneous clearance of the HPV follow the suppressive therapy of a recurrent HSV infection with acyclic nucleosides. Study design. We carried out a parallel observational study from 2015 to 2017. Herpes suppressive therapy with acyclic nucleosides (valacyclovir of 500 mg per day) during a 6 months is used to treat patients (n=32) aged 28 to 34 years (mean age 30.4±2.1 years) who have recurrent genital HSV infection and HPV infection both. The detection of HPV by RT-PCR before and after ant-herpetic therapy was investigated. Results. After treatment of HSV infection eradication of the one types of HPV was achieved in 43.75% cases, eradication of HPV-16 was achieved only in 15.4% (in 2 out of 13 patients) of cases, eradication HPV-18 was achieved in 25% (in 4 out of 16 patients) of cases. Decreasing of viral load occurred in 62.5% patients, full HPV-clearance was recorded in 15.6% of patients, but the high viral-load of HPV infection was preserved in 37.5% of the cases.</p></abstract><trans-abstract xml:lang="ru"><p>На сегодняшний день не существует методов лечения папилломавирусной инфекции (ПВИ). По накопленным научным данным известно, что у 80% инфицированных вирусом папилломы человека (ВПЧ) пациенток наблюдается спонтанный клиренс инфекции, что связано в том числе и с детерминированным иммунным ответом. По данным эпидемиологических исследований, герпес-вирусная инфекция, локализованная в области гениталий, является фактором риска персистенции ПВИ. Нами с 2015 по 2017 г. проведено параллельное исследование по изучению влияния противогерпетической терапии ациклическими нуклеозидами в супрессивном режиме у пациенток (n=32) в возрасте от 28 до 34 лет (средний возраст - 30,4±2,1 года) с рецидивирующей герпетической инфекцией, локализованной в области гениталий, на течение сопутствующей ПВИ. Всем пациенткам назначался валацикловир в профилактическом режиме по 500 мг/сут в течение не менее 6 мес. После терапии герпес-вирусной инфекции констатирована элиминация не менее 1 типа ВПЧ у 14 (43,75%) пациенток, элиминация 16-го типа вируса была достигнута только в 15,4% случаев, 18-го - в 25%. Снижение вирусной нагрузки ВПЧ произошло у 20 (62,5%) пациенток, полная элиминация вируса зафиксирована у 15,6%. Значимая и высокая вирусная нагрузка ВПЧ сохранялась у 31,3 и 37,5% пациенток соответственно.</p></trans-abstract><kwd-group xml:lang="en"><kwd>valacyclovir</kwd><kwd>Valvir</kwd><kwd>herpes</kwd><kwd>human papilloma virus</kwd><kwd>TLR</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>валацикловир</kwd><kwd>Валвир</kwd><kwd>герпес</kwd><kwd>вирус папилломы человека</kwd><kwd>toll-подобные рецепторы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Van Der Pol B. Sexually transmitted infections in women. Scand J Clin Lab Invest Suppl 2014; 74 (244): 68-74.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Тапильская Н.И., Воробцова И.Н., Гайдуков С.Н., Прошин С.Н. Оценка эффективности и безопасности применения имихимода в лечении субклинических и клинических проявлений персистирующей папилломавирусной инфекции шейки матки у пациенток раннего репродуктивного возраста // Гинекология. 2015; 17 (1): 14-7.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rawls W, Tompkins W, Figueroa M, Melnick J. Herpesvirus type 2: association with carcinoma of the cervix. Science (New York, NY) 1968; 161 (847): 1255.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 1982; 320 (8312): 1370-2.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Vonka V, Kanka J, Hirsch I et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer 1984; 33 (1): 61-6.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lehtinen M, Koskela P, Jellum E et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case - control study in the Nordic countries. Am J Epidemiol 2002: 156 (8): 687-92.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cao S, Gan Y, Dong X, Lu Z. Herpes simplex virus type 2 and the risk of cervical cancer: a meta - analysis of observational studies. Arch Gynecol Obstet 2014; 290: 1059-66. DOI 10.1007/s00404-014-3365-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Smith J.S, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hoffmann M, Quabius E.S, Tribius S et al. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep 2013; 29: 1962-8.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Генитальный герпес. Под ред. А.А.Кубановой. Клинические рекомендации. Российское общество дерматовенерологов. М.: ДЭКС-Пресс, 2010.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hibma M.H. The immune response to papillomavirus during infection persistence and regression. Open Virol J 2012; 6: 241-8. DOI: 10.2174/1874357901206010241</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Amador-Molina A, Hernández-Valencia J.F, Lamoyi E et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013; 5 (11): 2624-42. DOI: 10.3390/v5112624</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Прошин С.Н., Глушаков Р.И., Шабанов П.Д. и др. Значение экспрессии TLR-рецепторов для выбора фармакологической коррекции патологии шейки матки и эндометрия. Гены и клетки. 2011; 6 (1): 91-7.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wahid B, Ali A, Idrees M, Rafique S. Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. Cell Immunol 2016; 310: 1-13. DOI: 10.1016/j.cellimm.2016.08.001</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Jemon K, Leong C.M, Ly K et al. Suppression of the CD8+ T cell response by human papillomavirus type 16 E7 occurs in Langerhans cell - depleted mice. Sci Rep 2016; 6: 34789. DOI: 10.1038/srep34789</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Guidry J.T, Scott R.S. The interaction between human papillomavirus and other viruses. Virus Res 2017; 231: 139-47. DOI: 10.1016/j.virusres.2016.11.002</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Joseph G Skeate, Tania B et al. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol 2016; 97: 422-34. DOI: 10.1099/jgv.0.000341</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Woodham A.W, Raff A.B, Raff L.M et al. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol 2014: 192: 4748-57.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mesquita P.M.M, Preston-Hurlburt P, Keller M.J et al. Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection. J Infect Dis 2017; 215 (4): 614-22. DOI: https://doi.org/10.1093/infdis/jiw612</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Huang H.S, Lambert P.F. Use of an in vivo animal model for assessing the role of integrin a6b4 and syndecan-1 in early steps in papillomavirus infection. Virology. 2012; 433: 395-400.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Cermelli C, Orsi C.F, Ardizzoni A et al. Herpes simplex virus type 1 dysregulates antifungal defenses preventing monocyte activation and downregulating toll - like receptor-2. Microbiol Immunol 2008; 52 (12): 575-84.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Shannon B, Gajer P, Yi TJ et al. Distinct effects of the cervicovaginal microbiota and herpes simplex type 2 infection on female genital tract immunology. J Infect Dis 2017; 215 (9): 1366-75. DOI: https://doi.org/10.1093/infdis/jix088</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Plotkin B.J, Sigar I.M, Tiwari V, Halkyard S. Herpes simplex virus (HSV) modulation of Staphylococcus aureus and Candida albicans initiation of HeLa 299 cell - associated biofilm. Curr Microbiol 2016; 72: 529-37. DOI 10.1007/s00284-015-0975-7</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Satapathy S, Batra J, Jeet V et al. MicroRNAs in HPV associated cancers: small players with big consequences. Expert Rev Mol Diagn 2017; 17 (7): 711-22. DOI: 10.1080/14737159.2017.1339603</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Косарев В.В., Бабанов С.А. Клиническая фармакология и рациональная фармакотерапия. М.: Вузовский учебник; ИНФРА-М, 2012.</mixed-citation></ref></ref-list></back></article>
